Last checked at 
LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday.
Allergy said its house dust mite product is sold in a named patient programme in Spain. In the study across 10 sites in the country 43% of the 141 patients tested showed a decline in symptoms after one year.
Further, 17% of an asthmatic subgroup showed more moderate symptoms compared to the 51% baseline.
Allergy said no patients had any serious adverse side effect nor did any have to stop treatment during testing.
The company is presenting the data at the 37th annual congress of the European Academy of Allergy & Clinical Immunology in Munich on Tuesday.
Chief Executive Manuel Llobet said: "We are excited to be sharing our latest research at EAACI, demonstrating the breadth of our unique allergen immunotherapy company.
"The positive new data on our modified house-dust mite immunotherapy and our recent announcement on the success of our grass G205 dose-finding clinical study confirms that our novel allergen-specific immunotherapies are formulated to the optimal strength, and we believe Allergy Therapeutics has the potential to transform allergy treatment with optimised-dose, well-characterised, aluminium-free, convenient products."
Shares were up 5.9% on Tuesday at 27.00 pence each.
